Suppression of chronic experimental autoimmune neuritis by nasally administered recombinant rat interleukin-6

Απλή σελίδα τεκμηρίου
dc.contributor.authorDeretzi, G.en
dc.contributor.authorPelidou, S.en
dc.contributor.authorZou, L.en
dc.contributor.authorQuiding, C.en
dc.contributor.authorMix, E.en
dc.contributor.authorLevi, M.en
dc.contributor.authorWahren, B.en
dc.contributor.authorZhu, J.en
dc.date.accessioned2015-11-24T18:49:39Z
dc.date.available2015-11-24T18:49:39Z
dc.identifier.issn0019-2805-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/17990
dc.rightsDefault Licence-
dc.subjectAdministration, Intranasalen
dc.subjectAnimalsen
dc.subjectAutoimmune Diseases/immunology/pathology/*therapyen
dc.subjectChronic Diseaseen
dc.subjectDose-Response Relationship, Immunologicen
dc.subjectImmunoglobulin G/biosynthesisen
dc.subjectImmunosuppressionen
dc.subjectInterleukin-6/*therapeutic useen
dc.subjectMaleen
dc.subjectNeuritis, Autoimmune, Experimental/immunology/pathology/*therapyen
dc.subjectRatsen
dc.subjectRats, Inbred Lewen
dc.subjectRecombinant Proteins/therapeutic useen
dc.subjectSciatic Nerve/pathologyen
dc.subjectT-Lymphocyte Subsets/immunologyen
dc.subjectTumor Necrosis Factor-alpha/metabolismen
dc.titleSuppression of chronic experimental autoimmune neuritis by nasally administered recombinant rat interleukin-6en
heal.abstractExperimental autoimmune neuritis (EAN) is a CD4+ T-cell-mediated demyelinating disease of the peripheral nervous system (PNS) and serves as experimental model for human immune-demyelinating neurophathies, especially the Guillain-Barre syndrome. In this study, we examined the effect of recombinant rat interleukin-6 (rrIL-6) on chronic EAN in Lewis rats induced by immunization with P2 peptide 57-81 and Freund's complete adjuvant (FCA). Nasal administration of rat rIL-6 (1 microg/rat/day) beginning in the initial phase of EAN as a therapeutic agent, decreased the severity and the duration of clinical EAN. Low-grade inflammation and suppression of regional demyelination within the sciatic nerves were seen in rrIL-6-treated rats. Hyporesponsiveness of lymph node T cells, down-regulation of serum tumour necrosis factor-alpha (TNF-alpha) and increased levels of P2-specific immunoglobulin G1 (IgG1) antibodies document that nasal administration of rrIL-6 was effective systemically. However, because of the non-specific nature of the treatment and multiple effects of IL-6, more experience and great caution are needed, before nasal administration of IL-6 can be considered as a treatment of human autoimmune demyelinating neurophathies.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10447716-
heal.journalNameImmunologyen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1999-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ